SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Eris Lifesciences - Quaterly Results

02 Aug 2024 Evaluate
The Revenue for the quarter ended  June 2024 of Rs. 4566.90 millions grew by 11.04 % from Rs. 4112.90 millions.A radical decline of -84.62% was reported in the net profit of the company for the quarter ended June 2024 to Rs. 170.40  millions from Rs. 1107.60 millions.Operating profit for the quarter ended June 2024 decreased to 1285.40 millions as compared to 1595.40 millions of corresponding quarter ended June 2023.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202406 202306 % Var 202406 202306 % Var 202403 202303 % Var
Sales 4566.90 4112.90 11.04 4566.90 4112.90 11.04 14867.06 13307.25 11.72
Other Income 51.60 40.30 28.04 51.60 40.30 28.04 348.28 172.64 101.74
PBIDT 1285.40 1595.40 -19.43 1285.40 1595.40 -19.43 4886.42 5223.78 -6.46
Interest 561.70 68.40 721.20 561.70 68.40 721.20 574.20 208.10 175.93
PBDT 723.70 1527.00 -52.61 723.70 1527.00 -52.61 4312.22 5015.68 -14.03
Depreciation 455.50 201.60 125.94 455.50 201.60 125.94 1023.89 646.57 58.36
PBT 268.20 1325.40 -79.76 268.20 1325.40 -79.76 3288.33 4369.11 -24.74
TAX 97.80 217.80 -55.10 97.80 217.80 -55.10 291.21 389.03 -25.14
Deferred Tax 50.90 0.40 12625.00 50.90 0.40 12625.00 -285.23 -375.93 -24.13
PAT 170.40 1107.60 -84.62 170.40 1107.60 -84.62 2997.12 3980.08 -24.70
Equity 136.10 136.00 0.07 136.10 136.00 0.07 136.03 135.99 0.03
PBIDTM(%) 28.15 38.79 -27.44 28.15 38.79 -27.44 32.87 39.26 -16.27

Eris Lifesciences Share Price

1446.50 -18.90 (-1.29%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×